Oscotec Inc
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more
Oscotec Inc (039200) - Total Liabilities
Latest total liabilities as of September 2025: ₩31.19 Billion KRW
Based on the latest financial reports, Oscotec Inc (039200) has total liabilities worth ₩31.19 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oscotec Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Oscotec Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oscotec Inc Competitors by Total Liabilities
The table below lists competitors of Oscotec Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kent Gida Maddeleri Sanayi ve Ticaret AS
IS:KENT
|
Turkey | TL408.76 Million |
|
Home First Finance Company India Limited
NSE:HOMEFIRST
|
India | ₹100.87 Billion |
|
TripAdvisor Inc
NASDAQ:TRIP
|
USA | $1.98 Billion |
|
CVS Group plc
PINK:CVSGF
|
USA | $434.80 Million |
|
Karoon Energy Ltd
PINK:KRNGY
|
USA | $741.10 Million |
|
PG Electroplast Limited
NSE:PGEL
|
India | ₹17.63 Billion |
|
Fastighets AB Balder Series B
LSE:0H2Z
|
UK | Skr146.66 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Oscotec Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oscotec Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oscotec Inc (2011–2024)
The table below shows the annual total liabilities of Oscotec Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩38.42 Billion | +1.47% |
| 2023-12-31 | ₩37.86 Billion | +78.36% |
| 2022-12-31 | ₩21.23 Billion | +5.40% |
| 2021-12-31 | ₩20.14 Billion | -13.70% |
| 2020-12-31 | ₩23.34 Billion | +10.58% |
| 2019-12-31 | ₩21.11 Billion | -11.95% |
| 2018-12-31 | ₩23.97 Billion | +24.17% |
| 2017-12-31 | ₩19.30 Billion | +33.23% |
| 2016-12-31 | ₩14.49 Billion | -35.84% |
| 2015-12-31 | ₩22.58 Billion | +55.88% |
| 2014-12-31 | ₩14.49 Billion | -6.44% |
| 2013-12-31 | ₩15.48 Billion | -16.66% |
| 2012-12-31 | ₩18.58 Billion | -16.50% |
| 2011-12-31 | ₩22.25 Billion | -- |